Search

Displaying results 651 - 660 of 10000 in total
  1. Drug

    Lovastatin

    go.drugbank.com/drugs/DB00227
    ApprovedInvestigational

    were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while lovastatin has been found to have an average decrease in LDL-C of 25-40%. … [A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsSynonyms: (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate, 2β,6α-dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone
  2. Drug

    Olopatadine

    go.drugbank.com/drugs/DB00768
    Approved

    An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. … It is a structural analog of [doxepin], which has a minimal anti-allergic activity.

    Mixtures: OFNOL FRESH % 0.1 + %0.15 STERİL OFTALMİK ÇÖZELTİ, 1 ADETCategories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  3. Drug

    Enoxaparin

    go.drugbank.com/drugs/DB01225
    ApprovedInvestigational

    Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. … Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.

    Mixtures: ENOXAPARINA SODICA 40 MG JERINGAS PRELLENADASProducts: LOVENOX 50.000 IE (500 mg)/5 ml Injektionslösung in einer Durchstichflasche, ENOXALOW® 20 MG
  4. Drug

    Atropine

    go.drugbank.com/drugs/DB00572
    ApprovedInvestigationalVet approved

    Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active. … [A251660] Atropine is a relatively inexpensive drug and is included in the World Health Organization List of Essential Medicines.[A251675]

    Mixtures: LOMOTİL 2,5 MG + 0,025 MG / 5 ML ORAL ÇÖZELTİ, 60 ML, SUN-DIANOX TABLETProducts: MIDRISOL %1 GÖZ DAMLASI, 5 ML, ATROSED % 1 OFTALMIK ÇÖZELTI, 5 ML
  5. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    [L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. … [L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385].

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersProducts: ACTEMRA 400 MG/20 ML IV INFUZYONLUK COZELTI KONSANTRESI İÇEREN FLAKON, 1 ADET, ACTEMRA 400 MG/20 ML IV INFUZYONLUK COZELTI KONSANTRESI İÇEREN FLAKON, 4 ADET
  6. Drug

    Dihydroergotamine

    go.drugbank.com/drugs/DB00320
    ApprovedInvestigational

    formulated at 75% of the strength of the existing intranasal product. … [A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution

    Categories: Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT2 Receptor AgonistsSynonyms: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide, 5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman
  7. Drug

    Diltiazem

    go.drugbank.com/drugs/DB00343
    ApprovedInvestigational

    Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. … [T28] Being a potent vasodilator, diltiazem is used clinically as an antihypertensive, anti-arrhythmic, and as an anti-anginal agent [L6289] for the management of cardiovascular conditions such as hypertension

    Categories: Heterocyclic Compounds, 2-Ring, P-glycoprotein inhibitorsSynonyms: (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one, (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate
  8. Drug

    Edoxaban

    go.drugbank.com/drugs/DB09075
    ApprovedInvestigational

    (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. … Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for

    Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingProducts: LIXIANA 15 MG, LIXIANA FILM-COATED TABLET 15 MG
  9. Drug

    DL-alpha tocopheryl acetate

    go.drugbank.com/drugs/DB14477
    Approved

    Mixtures: Folika-MG, Davimet-MCategories: Vitamin E
  10. Drug

    Nimesulide

    go.drugbank.com/drugs/DB04743
    ApprovedWithdrawn

    Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. … Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.

    Mixtures: FRENAG PLUS %1+%5 SPREY, 50 ML, NIMOKAIN %1 + %5 JEL, 50 GCategories: Selective Cyclooxygenase 2 Inhibitors (NSAIDs), Cytochrome P-450 Substrates